Mental Disorders

WHO Dementia Prevention Guidelines Updated

To reduce the risk of cognitive decline and/or dementia specifically, the WHO just released updated guidance and dementia-specific recommendations: cognitive training may be offered to older adults with normal cognition or mild cognitive impairment and engagement in cognitive stimulation may be encouraged. Engagement in social activity interventions may be recommended. Physical activity should be recommended to adults with normal cognition and may be recommended to adults with mild cognitive impairment. Interventions aimed at reducing or ceasing hazardous and harmful drinking may be offered. Interventions for tobacco cessation should be offered to adults who use tobacco. A healthy, balanced dietary pattern may be recommended, but supplementation of vitamins B and E, omega-3 polyunsaturated fatty acids (PUFA) and multivitamins/minerals is not recommended. Interventions for reducing midlife overweight or obesity may be offered and dietary restriction interventions may be offered to adults who are overweight or obese. Management of diabetes, hypertension, dyslipidaemia at midlife, may be offered. Hearing aids may be offered to adults with hearing loss. Menopausal hormone therapy is not recommended in postmenopausal women aged 65 years and older. Reducing exposure to household and ambient air pollution may reduce the risk or incidence of cognitive decline and/or dementia. Tailored, multidomain interventions may be offered. Source: https://www.who.int/

hyangiu

Recent Posts

Intensive BP Control Reduces Cardiovascular Events After Ischemic Stroke

Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…

20 hours ago

No Significant Reduction in Major Cardiovascular Events with Intensive BP Lowering in T2D

In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…

20 hours ago

Stopping Statins Noninferior to Continuing Them in Older Adults without Known CVD

Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…

22 hours ago

Ziltivekimab and Pelacarsen Show No Clinical Benefit Despite Effective Biomarker Lowering

Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…

2 days ago

Cold Drives Heart Failure Hospitalizations in Older US Adults

Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…

6 days ago

No Significant Difference Between Initial CTO-PCI and No CTO-PCI Strategies in 10-Year Follow-Up

In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…

6 days ago

This website uses cookies.